95
Participants
Start Date
February 27, 2017
Primary Completion Date
November 5, 2019
Study Completion Date
November 5, 2019
Octagam 10%
Patients to be treated with Octagam 10%
Placebo
Patients to be treated with a Placebo
Charité-Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, Berlin
Octapharma Research Site, Great Neck
Octapharma Research Site, Pittsburgh
NeuroMedical Research Center, Panama City
Octapharma Research Site, Orlando
Octapharma Research Site, Plantation
University of South Florida, Tampa
Stones River Dermatology, Murfreesboro
Octapharma Research Site, Sumy
Octapharma Research Site, Ternopil
Octapharma Research Site, Ann Arbor
Uniklinikum Münster, Klinik für Hautkrankheiten, Münster
Octapharma Research Site, Rochester
Octapharma Research Site, Kansas City
Octapharma Research Site, Ivano-Frankivsk
Arthritis & Osteoporosis Clinic, Waco
Octapharma Research Site, Houston
Austin Neuromuscular Center, Austin
Octapharma Research Site, Lviv
Octapharma Research Site, Los Angeles
Octapharma Research Site, Huntington Beach
University of California -Irvine, Orange
Octapharma Research Site, Portland
Scientific Research Institute for Rheumatology (Moscow), Moscow
I.M. Sechenov First Moscow State Medical University, Moscow
3rd Rheumatology Department Of Clinical Rheumatology Hospital No. 25, Saint Petersburg
AVA-Peter clinic (Saint-Petersburg), Saint Petersburg
Octapharma Research Site, Cluj-Napoca
Orenburg State Medical University Based On Regional Clinical Hospital, Orenburg
Octapharma Research Site, Montreal
Revmatologický ústav, Prague
Semmelweis University Dermatology Clinic, Budapest
University of Debrecen Dept of Internal Medicine, Debrecen
University of Szeged Dermatology Clinic, Szeged
Academic Medical Centre University of Amsterdam, Amsterdam
Centrum Medyczne Plejady, Krakow
Narodowy Instytut Geriatrii, Reumatologii I Rehabilitacji - Warsaw, Warsaw
Lead Sponsor
Octapharma
INDUSTRY